ITRM970390A0 - - Google Patents

Info

Publication number
ITRM970390A0
ITRM970390A0 ITRM970390A ITRM970390A ITRM970390A0 IT RM970390 A0 ITRM970390 A0 IT RM970390A0 IT RM970390 A ITRM970390 A IT RM970390A IT RM970390 A ITRM970390 A IT RM970390A IT RM970390 A0 ITRM970390 A0 IT RM970390A0
Authority
IT
Italy
Application number
ITRM970390A
Other languages
Italian (it)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITRM970390A0 publication Critical patent/ITRM970390A0/it
Priority to IT97RM000390A priority Critical patent/IT1293067B1/it
Priority to PCT/IT1998/000163 priority patent/WO1999001126A1/en
Priority to EP05105620A priority patent/EP1623708A3/en
Priority to IL13349298A priority patent/IL133492A/en
Priority to US09/446,806 priority patent/US6180680B1/en
Priority to CA002295748A priority patent/CA2295748A1/en
Priority to EP98929631A priority patent/EP0983066A1/en
Priority to KR10-1999-7012633A priority patent/KR100539066B1/ko
Priority to JP50684499A priority patent/JP2002507223A/ja
Priority to NZ501844A priority patent/NZ501844A/en
Priority to AU79310/98A priority patent/AU726822B2/en
Publication of ITRM970390A1 publication Critical patent/ITRM970390A1/it
Application granted granted Critical
Publication of IT1293067B1 publication Critical patent/IT1293067B1/it
Priority to US10/928,156 priority patent/US20050026846A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT97RM000390A 1997-01-07 1997-07-01 Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico IT1293067B1 (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IT97RM000390A IT1293067B1 (it) 1997-07-01 1997-07-01 Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
EP98929631A EP0983066A1 (en) 1997-07-01 1998-06-18 Pharmaceutical composition comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
JP50684499A JP2002507223A (ja) 1997-07-01 1998-06-18 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルｌ−カルニチンをスタチンと組み合わせて含む医薬組成物
IL13349298A IL133492A (en) 1997-07-01 1998-06-18 Pharmaceutical preparations containing alkanol L - carnitine in combination with a statin for the treatment of diseases caused by a change in lipid metabolism
US09/446,806 US6180680B1 (en) 1997-07-01 1998-06-18 Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
CA002295748A CA2295748A1 (en) 1997-07-01 1998-06-18 Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
PCT/IT1998/000163 WO1999001126A1 (en) 1997-07-01 1998-06-18 Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
KR10-1999-7012633A KR100539066B1 (ko) 1997-07-01 1998-06-18 비정상적 지질대사-유래 질환치료에 유용한 스타틴과알카노일 ｌ-카르니틴 함유 약제 조성물
EP05105620A EP1623708A3 (en) 1997-07-01 1998-06-18 Pharmaceutical composition comprising acetyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
NZ501844A NZ501844A (en) 1997-07-01 1998-06-18 Alkanoyl L-carnitine in combination with a statin (simvastatin, lovastatin, provastatin or fluvastatin) for treating abnormal lipid metabolism disorders
AU79310/98A AU726822B2 (en) 1997-07-01 1998-06-18 Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
US10/928,156 US20050026846A1 (en) 1997-01-07 2004-08-30 Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97RM000390A IT1293067B1 (it) 1997-07-01 1997-07-01 Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico

Publications (3)

Publication Number Publication Date
ITRM970390A0 true ITRM970390A0 (en:Method) 1997-07-01
ITRM970390A1 ITRM970390A1 (it) 1999-01-01
IT1293067B1 IT1293067B1 (it) 1999-02-11

Family

ID=11405149

Family Applications (1)

Application Number Title Priority Date Filing Date
IT97RM000390A IT1293067B1 (it) 1997-01-07 1997-07-01 Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico

Country Status (10)

Country Link
US (2) US6180680B1 (en:Method)
EP (2) EP1623708A3 (en:Method)
JP (1) JP2002507223A (en:Method)
KR (1) KR100539066B1 (en:Method)
AU (1) AU726822B2 (en:Method)
CA (1) CA2295748A1 (en:Method)
IL (1) IL133492A (en:Method)
IT (1) IT1293067B1 (en:Method)
NZ (1) NZ501844A (en:Method)
WO (1) WO1999001126A1 (en:Method)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
PL197899B1 (pl) * 1999-06-08 2008-05-30 Sigma Tau Ind Farmaceuti Zastosowanie przeciwlipemiczne środka zawierającego statyny i karnityny
ES2237073T3 (es) * 1999-06-30 2005-07-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinacion con actividad hipolipemiante sustancialmente exenta de efectos toxicos o secundarios inducidos por farmacos hipolimiantes.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITRM20040307A1 (it) 2004-06-23 2004-09-23 Sigma Tau Ind Farmaceuti Confezione per almeno due prodotti differenti da vendere e utilizzare insieme.
CN101616665B (zh) * 2007-02-27 2013-03-27 希格马托制药工业公司 可用于治疗2型糖尿病的组合物
PL2136798T3 (pl) 2007-03-21 2015-11-30 Alfasigma Spa Kompozycja użyteczna do zapobiegania cukrzycy typu 2 i jej powikłań u pacjentów w stanie przedcukrzycowym z insulinoopornością
RU2329051C1 (ru) * 2007-04-02 2008-07-20 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Композиция, обладающая гиполипидемической и гепатопротекторной активностью
JP5677856B2 (ja) 2008-02-29 2015-02-25 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 医薬組成物
CA3073802A1 (en) * 2017-08-23 2019-02-28 Gavish-Galilee Bio Applications Ltd. Compositions and methods for treating atherosclerotic cardiovascular disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel

Also Published As

Publication number Publication date
US6180680B1 (en) 2001-01-30
US20050026846A1 (en) 2005-02-03
IL133492A (en) 2004-07-25
EP1623708A2 (en) 2006-02-08
AU726822B2 (en) 2000-11-23
EP1623708A3 (en) 2006-02-15
ITRM970390A1 (it) 1999-01-01
NZ501844A (en) 2001-10-26
IT1293067B1 (it) 1999-02-11
EP0983066A1 (en) 2000-03-08
CA2295748A1 (en) 1999-01-14
KR20010014439A (ko) 2001-02-26
WO1999001126A1 (en) 1999-01-14
JP2002507223A (ja) 2002-03-05
IL133492A0 (en) 2001-04-30
AU7931098A (en) 1999-01-25
KR100539066B1 (ko) 2005-12-26

Similar Documents

Publication Publication Date Title
BE2018C032I2 (en:Method)
CH0944937H2 (en:Method)
BE2013C047I2 (en:Method)
IN182481B (en:Method)
BR9700653A (en:Method)
BR9701757A (en:Method)
CN3058025S (en:Method)
BY4238C1 (en:Method)
BY4349C1 (en:Method)
CN3053170S (en:Method)
CN3053500S (en:Method)
CN3053524S (en:Method)
CN3053525S (en:Method)
CN3053852S (en:Method)
CN3054099S (en:Method)
CN3054162S (en:Method)
CN3054556S (en:Method)
CN3054602S (en:Method)
CN3054902S (en:Method)
CN3055113S (en:Method)
CN3055123S (en:Method)
CN3055179S (en:Method)
CN3055389S (en:Method)
CN3055471S (en:Method)
CN3058088S (en:Method)

Legal Events

Date Code Title Description
0001 Granted